Kala Pharmaceuticals(KALA) - 2024 Q2 - Quarterly Results

Exhibit 99.1 KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update -- Closed $12.5 million private placement financing led by SR One with participation from ADAR1 Capital Management and another life sciences-focused investor – -- Cash resources of $54.2 million as of June 30, 2024, together with anticipated funding remaining from CIRM award, expected to fund operations into 4Q 2025 – -- Topline data from Phase 2b CHASE trial of KPI-012 for PCED targeted in Q1 2025 – ARLINGTON, ...